Low-level peripheral organ dose and its effect on second malignancies for patients undergoing radiation therapy have been reported in the literature. However, a comprehensive database outlining the treatment modalities, the tumor location, and a quantification of the overall relative risk of second malignancies is rather limited. In this work, we quantify the relative risks or percent likelihood of second malignancies for patients undergoing IMRT and conventional radiotherapy for four different tumor sites: breast, head and neck, lung, and prostate. We utilize Monte Carlo methods based on actual patient plans to compute the whole body effective dose equivalent for each plan and then deduce the percent likelihood of the occurrence of second malignancy. Based on an evaluation of over 30 actual patient plans and Monte Carlo simulations using 6, 10, and 18MV photon beam energies, we observed that the IMRT patients treated for head and neck cancer showed a 40% increase in risk for developing a second malignancy compared to those treated with conventional radiotherapy.
Introduction
New and sophisticated radiotherapy treatment modalities continue to emerge as new applications from engineering and computer science are implemented in radiation therapy delivery. In general, most of the new applications aim to provide the physician with a better control of the dose delivered to the tumor while minimizing the dose deposited to the surrounding normal tissues. Intensity Modulated Radiation Therapy (IMRT) is one of such technologies. IMRT achieves its goal by the design and implementation of a complex computer generated treatment plan delivered to the patient via a computer controlled multileaf collimator (MLC) system. When compared to conventional and to 3D conformal radiotherapy, IMRT can achieve far greater tumor dose conformity and lower toxicity to surrounding normal tissues (1-7). This has led to dose escalation studies and in some cases an adaptation of higher prescribed doses for certain tumors. A concern that has been raised with the utilization of IMRT is the increase in the peripheral dose (i.e., the dose outside the direct radiation fields). This is due to the higher number of Monitor Units (MU) required for IMRT delivery. A conventional radiotherapy plan involves mainly a few open fields. Typical treatments include two AP/PA parallel opposed fields and/or two R/L lateral fields leading to about 2-4 fields (field segments) in total. On the other hand, IMRT uses many beam directions (ports), ranging typically from five to nine, with about twelve field segments per port on average. It is therefore not uncommon to encounter an IMRT plan with over 100 field segments and over a thousand MUs.
Although the same dose is delivered to the target volume, the number of MUs or beam-on time required for IMRT far exceeds that used in a conventional plan. A direct consequence is the increase in the low level peripheral organ dose due to leakage radiation from the linac's head. Leakage radiation is the major contribution of the observed increase in the peripheral organ dose (8). This is the primary concern of IMRT and the focus of this work.
The link between low level peripheral organ dose for patients undergoing radiation therapy to second malignancies especially for patients with long term survival rates has been the subject of many studies. Brenner et al. (9) reported a 4-6% increase in second lung malignancies after prostate radiotherapy as compared to surgery and it was up to 15% higher for long term survivors, not taking into consideration other factors unrelated to radiation such as smoking. In another study for radiation therapy of the cervix, Boice et al. reported the risk of second malignancies in a wide range of organs and they observed that higher doses (in the order of Gy) increased the risk of stomach cancer and leukemia (10). Movsas et al. observed that 5.7% patients treated with radiation developed second tumors (11).
Although this low level peripheral organ dose versus second malignancy probabilities has been reported in the literature, a comprehensive database outlining the treatment modality, the tumor location and a quantification of the overall relative risk of second malignancies is rather limited. The outcome of this work is to quantify the relative risk of radiation induced second malignancies for patients undergoing IMRT and conventional treatment for tumors located at different sites commonly treated using IMRT namely prostate, head and neck, lung, and breast.
The relation between the peripheral absorbed organ doses to the percent likelihood of the occurrence of second malignancies will be explored using three different models as discussed in the next section. Furthermore, the influence of photon beam energy and the effect of the collimator leakage will be investigated.
Materials and Methods
The distribution of dose in the patient is achieved via the Monte Carlo method. First, EGS4/BEAM (12) was used to simulate the clinical photon beams based on two accelera-tor designs (Primus and Primart Siemens Medical Solutions, Concord, CA) with different nominal energies (6, 10, and 18 MV). The LINACs were modeled according to manufacturer's specifications with leaf width at isocenter of 1 cm, inter-leaf transmission of 0.60% (6MV), 1.0% (10MV), and 1.30% (18MV), intra-leaf transmission of 0.30% (6MV), 0.60% (10MV), and 0.90% (18MV). The verification of each linac model was compared against measured data taken in water using an ion chamber (Exradin A1SL Shonka).
In order to correctly account for the dose to the patient outside the treatment field, we introduced a radial particle fluence that extended beyond the largest available field size during the dose calculation. The calculated peripheral dose was compared against measurements in solid water at various depths and at various distances from the central axis using an ion chamber (8). Neutron contributions were not considered in this work, although at high photon energies, greater than 10MV, neutrons can be produced in the treatment head and will contribute to the out-of-field radiation.
In phantom measurements and Monte Carlo simulations that take into account neutron effects show that neutron relative contribution is dependent on the depth and distance from the edge of the treatment field. The relative contributions are significant at shallower depths and large distances away from the edge of the treatment field (13).
Two whole body CT scans were used for the Monte Carlo calculations: an average male and average female. The organs were contoured in order to obtain dose volume statistics. Corvus IMRT treatment plans were derived from our department's database. For each of the sites, prostate, head and neck, breast and lung cases, over 30 patient plans were evaluated and a representative plan was chosen. For each plan, a corresponding 3D conformal radiotherapy plan was also developed on the ADAC Pinnacle3 ® treatment planning system (Phillips, Fitchburg, WI). We used similar clinical objectives in the IMRT and conventional planning and the final dose distribution were renormalized so that 95% of the PTV received at least the prescribed dose. The derived treatment plan parameters and the whole body CT scan were used as inputs to the Monte Carlo simulation. The average female was used for the breast and the average male for the other cases. The dose was computed using EGS4/MCSIM (14) for each IMRT case and their corresponding 3D conformal radiotherapy technique in order to compare the two dose distributions. The dose to organs outside the treatment area was computed in each case and the dose statistics were recorded.
It should be noted that the derived treatment plan parameters, jaw settings, gantry and collimator rotation, beam isocenter, MLC leaf settings and number of monitor units per segment, et cetera, were directly applied on the whole body CT image set. The parameters were based on plan optimiza-tion performed on the clinical CT image sets. In the process, we assumed that the average whole body CT scan used in the Monte Carlo calculations is representative of a typical patient geometry. In the situation where the chosen clinical CT scan is significantly different from the Monte Carlo average whole body scan, a different strategy has to be used. This assumption was reasonable for our purposes but verification of the derived beam isocenters per plan on the coordinate system of the average CT scan was necessary to ensure proper location at the intended tumor site. Most importantly, the same beam isocenter was used for the IMRT as well as the conventional plans. The isocenter locations were verified using a visualization toolkit, MCSHOW (14).
A total of 48 different plans were developed and Monte Carlo code used to compute the dose distributions. We summarize the plans in Table 1 , where we have used MSF, the Modulation Scaling Factor, defined simply as the ratio of the total MUs used for an IMRT plan with respect to its conventional counterpart (15).The prescriptions used in this study were the same for all plans calculated for the same anatomical site. We planned so that 54 Gy are delivered to the 95% of the PTV in the case of the breast patient, 65 Gy to the 95% PTV for the lung case, 72Gy to the 95% PTV for the prostate case, and 60Gy to the 95% PTV for the head and neck case. After the dose is computed for each plan, the doses to each organ are recorded. The whole body effective dose equivalent (EDE) is obtained by applying the risk coefficients for each organ as follows:
where R i is the risk coefficient of the i th organ with organ dose D i in accordance with the recommendations of NCRP Report 116, summarized in Table II. Estimation of the percent likelihood of second malignancy is based on a conservative approach where we have used a 2% chance (16) of the occurrence of second malignancy per Sievert whole body effective dose equivalent. We did not use the recommended 5% likelihood of second malignancies by the ICRU since this is for the general public including children. Inclusion of an organ dose in the percent likelihood calculations depends on the particular model used. Three models are considered each with supporting experimental data as discussed below:
Model 1
This is based on a study performed on animals. The radiation induced risk of second malignancy is considered to first increase with absorbed dose and then falls off at higher doses due to the fact that the cells are completely destroyed and dead cells can not give rise to second malignancies (17). A similar trend based on women who were treated for cervical cancer and had an increased risk for developing leukemia was later reported (18, 19) . In this case, the risk was observed to increase up to 4Gy and then decrease at higher doses. To apply this model, we shall exclude all organs re- ceiving doses above 4Gy in the consideration of the percent likelihood of second malignancy.
Model 2
The risk of solid tumors is observed to first increase with dose and then shows a leveling off at 4 to 8Gy but does not decline thereafter (20) . Based on this model, we shall apply a cut-off value at 4Gy. This means that every organ that received a dose of 4Gy or higher shall be assigned an absorbed dose of 4Gy in the calculation of the risk of second malignancy.
Model 3
The third model is the most recent and is based on a biological model of dose dependent cancer risks incorporating carcinogenic effects, cell killing, and additionally proliferation and repopulation effects. The risk is shown to increase linearly with the absorbed dose at all dose values (21).
This model adopts a comprehensive approach to the problem by developing a biological model that takes into account cell killing at high doses that is mostly associated with the other models and as well proliferation and repopulation effects. It agrees fairly well with results of several studies of radiation-induced second cancers in Hodgkin's disease patients (22-24) compared to any of the traditional previous models described above. In order to apply this model, we will have to include every irradiated organ in the computation of the overall risk of second malignancy.
Results
The Monte Carlo calculations were performed with statistical uncertainties below 1% in all the calculations. Therefore, we have not included any detailed statistical uncertainty information in the results reported below.
Whole Body Effective Dose Equivalents (EDE)
Table III shows the effective dose equivalent for each model and anatomical site. The EDE is given for both the IMRT and conventional plans calculated using Monte Carlo. The estimated percent likelihood of second malignancies is also included for model 3. From our results, we observe that the EDE and the percent likelihood of second malignancies are higher for the IMRT delivery for almost all plans calculated.
Radiation-induced Second Malignancy and Beam Energy
The EDE and hence the risk of second malignancy is reduced for the higher energy plans. As shown in Table III , the percent likelihood decreases for almost all anatomical sites as the energy increases. Only the head and neck plans remain relatively constant. The greatest decrease is observed for the breast and the lung case. It should be noted that these calculations are considering the photon dose contributions only. Neutron dose becomes significant for high energy plans (18MV) and increases proportionally with the modulation scaling factor.
Investigating the Collimator Effect
The leakage contribution to the organ peripheral dose is a function of the collimator rotation during treatment. This effect was investigated by performing calculations at 0 deg and 90 deg collimator positions. Figures 3 and 4 show that the collimator leakage can significantly contribute to the EDE in certain cases. It is significant for the lung and breast cases but it does not play an important role for prostate and head and neck plans due to the fact that there are not many nearby critical organs that contribute to the whole body dose equivalent dose.
Discussion
Based on the estimated risk of second malignancies and whole body effective dose equivalent (Table III) , we can see that there is a strong dependence on the model used. Differences of up to 800% exist between the three models. The application of IMRT contributes from 5% to 300% more to the EDE as compared to conventional delivery. The breast IMRT contributes more to the EDE than the rest, due to the proximity of organs to the treatment volume. The risk of radiation induced malignancy is greater for patients undergoing IMRT compared to the conventionally treated patients using all three models. In particular, using the most conservative approach, the head and neck patients on average show a 40% increase in the risk of radiation induced malignancy while the prostate patients show a 30% increase in risk. The greatest increase in relative risk was for the lung patients in which the risk was about 2.7 times that observed in conventional therapy. The negligible difference in risk for the breast patient can be attributed to the low modulation (MSF = 1.04) of the breast IMRT plan.
The lung patient conventional plans were limited to a simple AP/PA field geometry because of cord tolerance. A standard approach applies a combination of AP/PA and oblique off-cord fields that may increase the risk of second malignancy compared to the latter. We repeated our calculations for the 6MV energy using the standard field geometry achieving the same prescription (65Gy) with 45Gy from AP/PA and 20Gy from the oblique off-cord fields and observed an insignificant 0.04% increase in the risk of second malignancy. Thus, the results reported are applicable for standard conventional lung plans.
Although not uniformly established, we observed on average a decrease in the risk of second malignancy as the beam energy increased from 6MV to 18MV for both treatment modalities ( Figs. 1 and 2) . This decrease can be accounted for in part by the reduction in the softer component of the beams and therefore reduced scatter for higher energies. It should be noted that for the high energy beams we have not included the neutron component in the dose calculations. The dose due to neutron contributions has been performed by Kry et al. (13, 25) . They have shown that the contribution of neutron is uniform outside the field but is dependent on the depth. In our cases the whole body effective dose equivalent due to neutrons for the high energy beams is not very significant because the nominal electron energy of the Siemens Primus linac is about 14 MeV. Hence, a rather conservative estimation according to Kry et al. (13, 25) for the high energy calculations should be: an additional 1.2 Sv to 2 Sv for the conventional treatments and 2.0 Sv to 3.0 Sv for the IMRT ones. The effect of collimator rotation illustrates the significance of proper modeling of the MLC transmission effects in treatment planning. It was found that the whole body effective dose equivalent for a given treatment site may change significantly depending on the rotation of the collimator as this determines which organs will be subjected to interleaf leakage ( Figs. 3 and 4 ).
It should be noted that this study was based on IMRT versus an equivalent conventional plan delivered on a SIEMENS LINAC. Our results indicate that beam modulation resulting in higher delivered monitor units is a dominant contributing factor in the overall risk of second malignancy. For example, the breast patients with a small MSF of 1.04 resulted in approximately 3% increase in relative risk for the IMRT compared to the conventional radiotherapy. On the other hand, the head and neck patients with an MSF of 7.04 resulted in a 40% increase in relative risk for the IMRT compared to the conventional radiotherapy. Beam modulation is a characteristic of most IMRT plans involving many delivery systems such as helical tomotherapy, Varian LINAC, et cetera. Furthermore, we understand that differences will exist between the different delivery systems and that special considerations should be taken into account when estimating the risks due to differences in the leakage through the MLC of each LINAC. While a comprehensive study involving all possible IMRT delivery systems is beyond the scope of this study, we can infer from our results that a similar trend will be observed between an IMRT versus conventional plan delivered on the same system provided an MSF factor greater than 1 is involved.
Finally, we emphasize the fact that other risk factors may influence the development of radiation-induced second malignancy such as the prescribed dose, fraction size, age at exposure, genetic factors associated with DNA, smoking at the time of radiation treatment, and concomitant chemotherapy (26). For example, higher prescribed doses lead to increased risk (27-29) while smaller fraction size results in lower risk (29) (30) (31) . The risk reported in this study is associated with radiotherapy type only. Furthermore, these are lifetime risk usually occurring 5 to 50 years following radiotherapy (26).
Conclusion
The excess in leakage radiation due to the application of IMRT causes an increase in the risk of second malignancies, which is proportional to the increase of number of MUs. From the computed risks of fatal cancer due to the application of IMRT we can see that there is substantial increase when compared to conventional treatments. The percent likelihood of second cancer is also increased with the complexity of the treatment plan. Plans with high Modulation Scaling Factor (MSF) will increase the whole body effective dose equivalent (and hence the risk of second malignancies) because the leakage from the linac's head will increase proportionally with the number of MUs required. The risk estimate used in our calculations, although conservative concerning the patient population undergoing radiation therapy, still needs to be verified through patient follow up data which will become available in the near future. Such data is not yet available due to the fact that IMRT is a relatively new technique. Accurate dose distributions obtained using Monte Carlo methods enabled us to investigate the total dose equivalent for various energies, and for various linac designs.
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